Articles

First and only pen device with half-unit dosing increments…. 

Eating healthy still the best route…. 

Sugar intake seems to promote the growth and spread of tumors in fruit flies through a few pathways….

High intensity physical activity in sessions less than 10 minutes can be as effective for losing weight as lower intensity exercise over a longer period of time….

New information on one of diabetes’ most debilitating complications…. Diabetic neuropathy affects approximately 60-70% of people with diabetes. For such a common problem that affects patients with diabetes, little is known about peripheral neuropathy. Patients with diabetes who are suffering from peripheral neuropathy talk of how terrible it is to …

Elevation in oxidative stress level can damage cell and tissue….

This study systemically reviewed randomized controlled trials and observational studies to evaluate whether actual exposure of metformin can be associated with cancer and cancer mortality in type 2 diabetes patients….

Women diagnosed with Polycystic Ovary Syndrome are at an increased risk of type 2 diabetes and cardiovascular disease….

Promising results from IDegLira and the DUAL I trial…. Novo Nordisk’s new drug IDegLira is a fixed-ratio combination of insulin degludec and the glucagonlike perptide-1 (GLP-1) agonist liraglutide. It combines the effects of insulin degludec and liraglutide in a once daily injection. In the Dual Action of Liraglutide and Insulin …

GLP-1 agonist may prove beneficial to type 1 diabetes….